Royal Bank of Canada’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-245
Closed 8044
2022
Q3
$0 Hold
245
﹤0.01% 8124
2022
Q2
$1K Sell
245
-28,457
-99% -$79.1K ﹤0.01% 7280
2022
Q1
$116K Buy
28,702
+5,595
+24% +$30.7K ﹤0.01% 5544
2021
Q4
$185K Buy
23,107
+9,050
+64% +$106K ﹤0.01% 5415
2021
Q3
$271K Buy
14,057
+5,752
+69% +$101K ﹤0.01% 4893
2021
Q2
$115K Buy
8,305
+8,255
+16,510% +$97.8K ﹤0.01% 5514
2021
Q1
$0 Buy
+50
New +$365 ﹤0.01% 7801
2020
Q4
Sell
-1
Closed 7389
2020
Q3
$0 Sell
1
-72
-99% -$241 ﹤0.01% 7077
2020
Q2
$0 Hold
73
﹤0.01% 7033
2020
Q1
$0 Buy
73
+53
+265% +$243 ﹤0.01% 7158
2019
Q4
$0 Sell
20
-34
-63% -$160 ﹤0.01% 7243
2019
Q3
$0 Buy
+54
New +$314 ﹤0.01% 7280
2018
Q3
Sell
-1
Closed 7061
2018
Q2
$0 Hold
1
﹤0.01% 6870
2018
Q1
$0 Hold
1
﹤0.01% 6946
2017
Q4
$0 Hold
1
﹤0.01% 7027
2017
Q3
$0 Buy
+1
New +$6 ﹤0.01% 7084
2017
Q2
Sell
-1
Closed 6864
2017
Q1
$0 Sell
1
-12
-92% -$130 ﹤0.01% 6899
2016
Q4
$0 Buy
+13
New +$478 ﹤0.01% 6847

Other funds holding PLXP

Royal Bank of Canada's PLXP Position: Q4 2022 in Review

Royal Bank of Canada sold out of PLx Pharma Inc. Common Stock (PLXP) in Q4 2022, closing a stake of 245 shares.

Royal Bank of Canada first reported a position in PLXP in Q4 2016 and held it in 18 quarters. The position peaked at $271K in Q3 2021. 41 funds tracked by Wall St. Rank hold PLXP as of Q4 2022.

  • Royal Bank of Canada reported no remaining PLx Pharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 245 PLx Pharma Inc. Common Stock shares in Q4 2022.
  • Royal Bank of Canada first reported a position in PLx Pharma Inc. Common Stock in Q4 2016 and held it in 18 quarters.
  • Royal Bank of Canada's PLx Pharma Inc. Common Stock position peaked at $271K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.